drugset / Trial / NCT05144360

Efficacy and Safety of Atenas Association in the Treatment of Type II Diabetes Mellitus and Hypertension

NCT05144360

Phase 3 Withdrawn EMS
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Atenas association in the treatment of type 2 diabetes mellitus and hypertension

Timeline

Start
2022-08
Primary completion
2024-07
Completion
2024-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amlodipine Other / unclassified 5 mg Oral
Subject Atenas Unknown Oral
Comparator Empagliflozin Small molecule 25 mg Oral
Comparator Telmisartan Other / unclassified 40 mg Oral
Comparator Telmisartan Other / unclassified 80 mg Oral